Le Lézard
Classified in: Health
Subjects: RCL, CFG

Information Update - Update: Pharmascience Inc. recalls certain lots of over-the-counter ranitidine


OTTAWA, ON, Dec. 3, 2021 /CNW/ - Pharmascience Inc. is recalling 18 lots of over-the-counter ranitidine drugs (75 mg and 150 mg tablets) after tests found NDMA, a nitrosamine impurity, close to and above the acceptable level. The products are sold under various private labels. Please refer to the Affected Products table for detailed information on the recalled lots.

Health Canada maintains a list of ranitidine drugs affected by this issue. Please see the full advisory for more information, including what consumers should do.

Affected Products

Product  Name

DIN

Strength

Lot

BIOMEDIC Acid Reducer (30 tablets)

02247551

75 mg

632952I

Life Brand Acid Reducer (30 tablets)

02247551

75 mg

632952K

OPTION+ Acid Reducer (10 tablets)

02247551

75 mg

632952B

OPTION+ Acid Reducer (40 tablets)

02247551

75 mg

633694B

Personnelle Acid Reducer (10 tablets)

02247551

75 mg

632952D

ATOMA maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

627765H

BIOMEDIC maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

627765I

BIOMEDIC maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

628471C

Compliments maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

628471D

CO-OP Care+ maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

627765D

Health One maximum strength acid reducer without prescription (32 tablets)

02293471

150 mg

628471A

London Drugs maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

627765E

Option+ maximum strength acid reducer without prescription (8 tablets)

02293471

150 mg

627765B

Option+ maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

627765G

PHARMASAVE maximum strength acid reducer without prescription (8 tablets)

02293471

150 mg

627765C

PHARMASAVE maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

628471B

Rexall maximum strength acid reducer without prescription (8 tablets)

02293471

150 mg

627765A

Rexall maximum strength acid reducer without prescription (24 tablets)

02293471

150 mg

627765F

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:03
THE IAMStm BRAND LAUNCHES ONLINE KITTEN AND PUPPY HUBS TO EMPOWER PET PARENTS IN CANADA WITH EXPERT INFORMATION
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
TELUS Health enables health data interoperability in Nova Scotia
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a CAGR of 21%, says Coherent Market Insights
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Sectra publishes Annual Report and Sustainability Report for 2023/2024
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

More news about Health...


News published on and distributed by: